Roles of CD4+ T cells as mediators of antitumor immunity

It has been well established that CD8+ T cells serve as effector cells of the adaptive immune response against tumors, whereas CD4+ T cells either help or suppress the generation of CD8+ cytotoxic T cells. However, in several experimental models as well as in cancer patients, it has been shown that...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 13; p. 972021
Main Authors Kravtsov, Dmitriy S, Erbe, Amy K, Sondel, Paul M, Rakhmilevich, Alexander L
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 09.09.2022
Subjects
adoptive cell therapy
CD4+ T cells
CD4-Positive T-Lymphocytes
CD8-Positive T-Lymphocytes
cytotoxicity
Humans
Immunology
immunotherapy
MHC
Neoplasms
T-Lymphocytes, Cytotoxic
MHC
CD4+ T cells
adoptive cell therapy
cytotoxicity
immunotherapy
Online AccessGet full text

Cover

More Information
Summary:It has been well established that CD8+ T cells serve as effector cells of the adaptive immune response against tumors, whereas CD4+ T cells either help or suppress the generation of CD8+ cytotoxic T cells. However, in several experimental models as well as in cancer patients, it has been shown that CD4+ T cells can also mediate antitumor immunity either directly by killing tumor cells or indirectly by activating innate immune cells or by reducing tumor angiogenesis. In this review, we discuss the growing evidence of this underappreciated role of CD4+ T cells as mediators of antitumor immunity.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-2
Edited by: Anna Pasetto, Karolinska Institutet (KI), Sweden
Reviewed by: Kaiting Yang, The University of Chicago, United States; Alexandre Corthay, Oslo University Hospital, Norway
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2022.972021